联合表皮生长因子受体（EGFR）抑制剂与含Src同源2结构域蛋白酪氨酸磷酸酶2（SHP2）或赖氨酸特异性去甲基化酶1（LSD1）抑制剂以克服癌症中的多药耐药性。 - Suppr

Suppr

超能文献

Combining EGFR inhibitors with SHP2 or LSD1 inhibitors to overcome multidrug resistance in cancer.

作者信息

Zhang Huiqing, Yang Xinyu, Song Yihui, Yu Bin

机构信息

School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, 450001, China.

出版信息

Future Med Chem. 2022 Apr;14(8):527-529. doi: 10.4155/fmc-2021-0326. Epub 2022 Mar 30.

DOI:10.4155/fmc-2021-0326

PMID:35350851

Abstract

摘要

相似文献

Combining EGFR inhibitors with SHP2 or LSD1 inhibitors to overcome multidrug resistance in cancer.

Future Med Chem. 2022 Apr;14(8):527-529. doi: 10.4155/fmc-2021-0326. Epub 2022 Mar 30.

Annual review of LSD1/KDM1A inhibitors in 2020.

Eur J Med Chem. 2021 Mar 15;214:113254. doi: 10.1016/j.ejmech.2021.113254. Epub 2021 Feb 3.

Advances toward LSD1 inhibitors for cancer therapy.

Future Med Chem. 2017 Jul;9(11):1227-1242. doi: 10.4155/fmc-2017-0068. Epub 2017 Jul 19.

Dioscin overcome TKI resistance in EGFR-mutated lung adenocarcinoma cells via down-regulation of tyrosine phosphatase SHP2 expression.

Int J Biol Sci. 2018 Jan 11;14(1):47-56. doi: 10.7150/ijbs.22209. eCollection 2018.

TCPs: privileged scaffolds for identifying potent LSD1 inhibitors for cancer therapy.

Epigenomics. 2016 May;8(5):651-66. doi: 10.2217/epi-2015-0002. Epub 2016 Apr 22.

Reversible Lysine Specific Demethylase 1 (LSD1) Inhibitors: A Promising Wrench to Impair LSD1.

J Med Chem. 2021 Mar 11;64(5):2466-2488. doi: 10.1021/acs.jmedchem.0c02176. Epub 2021 Feb 23.

Therapeutic potential of targeting LSD1/ KDM1A in cancers.

Pharmacol Res. 2022 Jan;175:105958. doi: 10.1016/j.phrs.2021.105958. Epub 2021 Oct 28.

Irreversible LSD1 Inhibitors: Application of Tranylcypromine and Its Derivatives in Cancer Treatment.

Curr Top Med Chem. 2016;16(19):2179-88. doi: 10.2174/1568026616666160216154042.

Targeting SHP2 for EGFR inhibitor resistant non-small cell lung carcinoma.

Biochem Biophys Res Commun. 2013 Oct 4;439(4):586-90. doi: 10.1016/j.bbrc.2013.09.028. Epub 2013 Sep 13.

Novel histone demethylase LSD1 inhibitors selectively target cancer cells with pluripotent stem cell properties.

Cancer Res. 2011 Dec 1;71(23):7238-49. doi: 10.1158/0008-5472.CAN-11-0896. Epub 2011 Oct 5.

引用本文的文献

Discovery of TK-642 as a highly potent, selective, orally bioavailable pyrazolopyrazine-based allosteric SHP2 inhibitor.

Acta Pharm Sin B. 2024 Aug;14(8):3624-3642. doi: 10.1016/j.apsb.2024.03.028. Epub 2024 Mar 26.

Harnessing the cyclization strategy for new drug discovery.

Acta Pharm Sin B. 2022 Dec;12(12):4309-4326. doi: 10.1016/j.apsb.2022.09.022. Epub 2022 Oct 7.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

Combining EGFR inhibitors with SHP2 or LSD1 inhibitors to overcome multidrug resistance in cancer.

Future Med Chem. 2022 Apr;14(8):527-529. doi: 10.4155/fmc-2021-0326. Epub 2022 Mar 30.

Annual review of LSD1/KDM1A inhibitors in 2020.

Eur J Med Chem. 2021 Mar 15;214:113254. doi: 10.1016/j.ejmech.2021.113254. Epub 2021 Feb 3.

Advances toward LSD1 inhibitors for cancer therapy.

Future Med Chem. 2017 Jul;9(11):1227-1242. doi: 10.4155/fmc-2017-0068. Epub 2017 Jul 19.

Dioscin overcome TKI resistance in EGFR-mutated lung adenocarcinoma cells via down-regulation of tyrosine phosphatase SHP2 expression.

Int J Biol Sci. 2018 Jan 11;14(1):47-56. doi: 10.7150/ijbs.22209. eCollection 2018.

TCPs: privileged scaffolds for identifying potent LSD1 inhibitors for cancer therapy.

Epigenomics. 2016 May;8(5):651-66. doi: 10.2217/epi-2015-0002. Epub 2016 Apr 22.

Reversible Lysine Specific Demethylase 1 (LSD1) Inhibitors: A Promising Wrench to Impair LSD1.

J Med Chem. 2021 Mar 11;64(5):2466-2488. doi: 10.1021/acs.jmedchem.0c02176. Epub 2021 Feb 23.

Therapeutic potential of targeting LSD1/ KDM1A in cancers.

Pharmacol Res. 2022 Jan;175:105958. doi: 10.1016/j.phrs.2021.105958. Epub 2021 Oct 28.

Irreversible LSD1 Inhibitors: Application of Tranylcypromine and Its Derivatives in Cancer Treatment.

Curr Top Med Chem. 2016;16(19):2179-88. doi: 10.2174/1568026616666160216154042.

Targeting SHP2 for EGFR inhibitor resistant non-small cell lung carcinoma.

Biochem Biophys Res Commun. 2013 Oct 4;439(4):586-90. doi: 10.1016/j.bbrc.2013.09.028. Epub 2013 Sep 13.

Novel histone demethylase LSD1 inhibitors selectively target cancer cells with pluripotent stem cell properties.

Cancer Res. 2011 Dec 1;71(23):7238-49. doi: 10.1158/0008-5472.CAN-11-0896. Epub 2011 Oct 5.

引用本文的文献

Discovery of TK-642 as a highly potent, selective, orally bioavailable pyrazolopyrazine-based allosteric SHP2 inhibitor.

Acta Pharm Sin B. 2024 Aug;14(8):3624-3642. doi: 10.1016/j.apsb.2024.03.028. Epub 2024 Mar 26.

Harnessing the cyclization strategy for new drug discovery.

Acta Pharm Sin B. 2022 Dec;12(12):4309-4326. doi: 10.1016/j.apsb.2022.09.022. Epub 2022 Oct 7.